Nebivolol 5mg Tablet
Description
NEBROOT-5
Nebivolol 5 mg Tablets
Division: DIABGLYM
Composition
Each tablet contains:
Nebivolol IP — 5 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Oral tablet
Product Description
NEBROOT-5 contains Nebivolol 5 mg, a third-generation highly selective beta-1 adrenergic receptor blocker formulated for the effective management of hypertension and long-term cardiovascular protection. Nebivolol offers a unique combination of beta-1 selective blockade and nitric oxide-mediated vasodilatory action, resulting in effective blood pressure reduction with improved endothelial function and vascular protection.
Nebivolol is widely prescribed in cardiology and internal medicine for patients with essential hypertension, coronary artery disease, heart failure, diabetes-associated hypertension, and cardiovascular risk reduction. It helps reduce heart rate, myocardial oxygen demand, cardiac workload, and peripheral vascular resistance while maintaining excellent tolerability and a favorable metabolic profile.
NEBROOT-5 is particularly beneficial for patients with hypertension associated with tachycardia, ischemic heart disease, left ventricular dysfunction, metabolic syndrome, diabetes, and patients requiring long-term beta-blocker therapy with vascular protective benefits.
Technical Knowledge of Nebivolol
Nebivolol selectively blocks beta-1 adrenergic receptors in the heart, reducing sympathetic stimulation, heart rate, myocardial contractility, and renin secretion. In addition to beta-blockade, Nebivolol stimulates endothelial nitric oxide release, producing vasodilation, improved endothelial function, enhanced arterial compliance, and reduced peripheral vascular resistance.
Unlike many traditional beta-blockers, Nebivolol has minimal adverse effects on glucose metabolism, lipid profile, and exercise tolerance, making it particularly suitable for patients with diabetes, metabolic syndrome, and cardiovascular comorbidities.
Mechanism of Action
Nebivolol selectively blocks beta-1 receptors, reduces heart rate and myocardial contractility, decreases cardiac output, suppresses renin release, stimulates nitric oxide-mediated vasodilation, improves endothelial function, and reduces peripheral vascular resistance.
Key Benefits
Effective reduction of systolic and diastolic blood pressure
Reduces heart rate and myocardial workload
Improves endothelial function
Provides nitric oxide-mediated vasodilation
Supports cardiovascular protection
Favorable metabolic profile
Convenient once-daily dosing
Suitable for long-term hypertension management under medical supervision
Clinical Applications
NEBROOT-5 is commonly prescribed for essential hypertension, hypertension with tachycardia, hypertension with coronary artery disease, hypertension with diabetes mellitus, metabolic syndrome, chronic heart failure, left ventricular dysfunction, and long-term cardiovascular risk reduction.
Facts About Nebivolol
Nebivolol is a modern third-generation beta-blocker with unique nitric oxide-mediated vasodilatory properties that distinguish it from conventional beta-blockers. Extensive clinical evidence demonstrates effective blood pressure reduction, improvement in endothelial function, and favorable cardiovascular outcomes. Its excellent tolerability and metabolic neutrality make it an important therapeutic option in contemporary hypertension management.
Key Facts
Third-generation highly selective beta-1 blocker
Nebivolol 5 mg for blood pressure and heart rate control
Nitric oxide-mediated vasodilatory action
Improves endothelial function and vascular health
Favorable metabolic and cardiovascular profile
Evidence-based antihypertensive and cardioprotective therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
NEBROOT-5 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, coronary artery disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this formulation.
Why Choose NEBROOT-5 for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Nebivolol 5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented formulation
Moisture-controlled tablet manufacturing
Blister and Alu-Alu packaging options
NEBROOT-5 from DIABGLYM combines effective blood pressure control, heart rate management, endothelial protection, evidence-based cardiovascular therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Nebivolol formulation.
